Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 824 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
Regulatory Filings
2026-05-06 Hebrew (modern)
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
Regulatory Filings
2026-05-06 Hebrew (modern)
Other Report or Announcement
Director's Dealing Classification · 94% confidence The document is an SEC Form 3 – an Initial Statement of Beneficial Ownership filed under Section 16(a) of the Securities Exchange Act, detailing personal share and option holdings by company directors/officers. This fits the insider reporting category for transactions by directors and executives. Therefore, it is a Director's Dealing filing.
2026-04-16 English
Other Report or Announcement
Report Publication Announcement Classification · 85% confidence The document is a short ‘‘Other Report or Announcement’’ filed under Israeli TASE/ISA rules, stating that a report (Form 3 filings binder) is attached. It does not contain the actual report data but merely notifies investors of its publication/attachment. This fits the definition of a Report Publication Announcement.
2026-04-16 English
Other Report or Announcement
Regulatory Filings
2026-04-10 Hebrew (modern)
Other Report or Announcement
Director's Dealing Classification · 90% confidence The document is filed under Regulation 5 of the Securities Regulations for a foreign private issuer and explicitly states “Attached hereto is a report on Form 4s.” U.S. Form 4 is used for insider share transactions by company directors and executives. This clearly matches the definition for ‘Director’s Dealing’ filings.
2026-04-10 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.